Molecular Therapy Oncology

Enhancing cancer killing and natural killer cell persistence by targeting NOXA, a predictor of poor patient survival.

A monoclonal antibody W1 blocks mesothelin-mediated tumor progression.

Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy.

Recombinant CALR polarizes and activates macrophages in tumors.

Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression.

A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct.

Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD.

E3-19K 和 i-leader 中的效力增强突变增加了 PH20/SPAM1 武装溶瘤腺病毒 Ad5Δ24RGD 的细胞溶解活性。

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer

EpCAM-PSMA：转移性去势抵抗性前列腺癌中PSMA靶向α疗法治疗结果的潜在预测因子

Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells

NKG2A 和 FAS 的共编辑可增强 CAR NK 细胞的长期细胞毒性和持久性。

Directed evolution generates an oncolytic Sindbis virus with enhanced tumor-killing capacity in osteosarcoma.